Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$20 Mln
P/E Ratio
--
P/B Ratio
1.15
Industry P/E
79.79
Debt to Equity
0.71
ROE
-2.63 %
ROCE
--
Div. Yield
0 %
Book Value
0.24
EPS
-1.11
CFO
$-101.13 Mln
EBITDA
$-146.13 Mln
Net Profit
$-176.56 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Beyond Air (XAIR)
| -33.17 | -10.80 | -35.97 | -81.98 | -66.91 | -50.87 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Beyond Air (XAIR)
| -81.45 | -69.80 | -31.25 | 79.13 | 0.76 | 12.47 | -6.78 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.10 | 10,391.68 | 14.66 | 12.69 | |
| 71.01 | 9,766.86 | 94.68 | 2.52 | |
| 152.15 | 8,196.06 | -- | -25.23 | |
| 277.35 | 10,728.90 | 770.42 | 1.2 |
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company... offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York. Address: 900 Stewart Avenue, Garden City, NY, United States, 11530 Read more
CEO & Chairman of the Board
Mr. Steven Adam Lisi
CEO & Chairman of the Board
Mr. Steven Adam Lisi
Headquarters
Garden City, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Beyond Air Inc (XAIR) stood at $ 40 Mln as on 31-Dec-24
The share price of Beyond Air Inc (XAIR) is $0.24 (NASDAQ) as of 17-Apr-2025 16:13 EDT. Beyond Air Inc (XAIR) has given a return of -66.91% in the last 3 years.
Beyond Air Inc (XAIR) has a market capitalisation of $ 20 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Beyond Air Inc (XAIR) is 1.15 times as on 17-Apr-2025, a 65% discount to its peers’ median range of 3.27 times.
Since, TTM earnings of Beyond Air Inc (XAIR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Beyond Air Inc (XAIR) and enter the required number of quantities and click on buy to purchase the shares of Beyond Air Inc (XAIR).
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York. Address: 900 Stewart Avenue, Garden City, NY, United States, 11530
The CEO & director of Mr. Steven Adam Lisi. is Beyond Air Inc (XAIR), and CFO & Sr. VP is Mr. Steven Adam Lisi.
There is no promoter pledging in Beyond Air Inc (XAIR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,070
|
|
|
1,049
|
|
|
978
|
|
|
820
|
| Beyond Air Inc. (XAIR) | Ratios |
|---|---|
|
Return on equity(%)
|
-293.86
|
|
Operating margin(%)
|
-1707.31
|
|
Net Margin(%)
|
-1730
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Beyond Air Inc (XAIR) was $0 Mln.
$0.01
(
